Third Rock Ventures has cut the ribbon on its latest startup, pledging $45 million to launch Cambridge, MA's Voyager Therapeutics, a gene therapy biotech with a promising platform for central nervous system treatments.
Building off research they performed in 2011, scientists at the California Institute of Technology showed that they can use an antibody delivery method to combat HIV across mucosal surfaces. The technique could help prevent vaginal transmission of the virus in humans, according to a university report.
Looking beyond the small-molecule drugs and biologic treatments that have dominated therapeutic development over the past generation, GlaxoSmithKline's all-encompassing R&D department is trying to get a jump on the future of medicine, and research chief Moncef Slaoui is betting that there's a great deal of promise in drug-mimicking electronics.
San Diego drug delivery company Sonrgy snagged exclusive rights to an ultrasound-based nanotech delivery platform conceived at the University of California, San Diego.
Researchers at MIT's Microsystems Technology Laboratory (MTL) and physicians from Harvard Medical School and the Massachusetts Eye and Ear Infirmary (MEEI) developed an innovative, low-power signal-processing chip that could provide an alternative to cochlear implants.
Sanofi hasn't had much to brag about when it comes to new product launches in the 5 years since Chris Viehbacher took the helm of the pharma giant. While he's tried, not always successfully, to reinvigorate R&D--buying Genzyme in the process--new therapies have added less than a billion euros a year to the top line, according to PMLive.
Last year, CRO BioClinica saw its most rapid growth in Europe, the company said, and now, as it prepares to join forces with CCBR-Synarc in its second merger in as many years, the clinical trial outfit plans to deepen its investment in the continent.
The British government has been unveiling a series of genomics and bioinformatics initiatives intended to revive its ailing biopharma industry. This week brought news of $52 million in funding for 5 bioinformatics projects run by British research institutes.
As more and more massive-selling biologics lose their patent protection, a new class of biosimilars is poised to blow up around the world, and the U.K.'s BioOutsource is amping up its capabilities to prepare for the boom.
France's Innate Pharma has signed a deal to pay Novo Nordisk $2.7 million up front and as much as $27 million in milestones for exclusive rights to the pair's Phase II-ready cancer immunotherapy.